# OnCo record nuclide-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/nuclide-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "nuclide-therapeutics" ;
  schema:name "Nuclide Therapeutics"@en ;
  schema:alternateName "Nuclide Tx"@en ;
  schema:description "Nuclide Therapeutics is a UK start-up developing radioactive drugs for cancers that have stopped responding to other treatments. Its lead medicine carries radioactive iodine and was moving towards first human trials in 2026."@en ;
  schema:url <https://onco.cc/companies/nuclide-therapeutics/>, <https://nuclidetx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://nuclidetx.com/>, <https://nuclidetx.com/news/launch-announcement>, <https://nuclidetx.com/news/latest-press-release>, <https://enamine.net/news-press-releases/press-releases/enamines-idd-platform-accelerates-nuclide-therapeutics-precision-radiotheranostics-pipeline-towards-the-clinic> ;
  schema:addressCountry "GB" ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/radioiodine-therapy/> .